T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response

Haematologica

Volumn 95, Issue 3, 2010, Pages 440-448

  Van Loo, Peter ^a,b   Tousseyn, Thomas ^c   Vanhentenrijk, Vera ^c   Dierickx, Daan ^c   Malecka, Agnieszka ^d   Bempt, Isabelle Vanden ^c   Verhoef, Gregor ^c   Delabie, Jan ^d   Marynen, Peter ^a,b   Matthys, Patrick ^e   De Wolf Peeters, Chris ^c  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF OSLO   (Norway)

^e REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Gene expression profiling; Hodgkin's lymphoma; THRLBCL

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; MONOCYTE CHEMOTACTIC PROTEIN 2; PROTEIN VSIG4; REGULATOR PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DENDRITIC CELL; DNA MICROARRAY; GENE EXPRESSION; HISTIOCYTE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INNATE IMMUNITY; LARGE CELL LYMPHOMA; MACROPHAGE; MAJOR CLINICAL STUDY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL HISTIOCYTE RICH LARGE B CELL LYMPHOMA; T LYMPHOCYTE; UPREGULATION;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; GENE EXPRESSION PROFILING; HISTIOCYTES; HODGKIN DISEASE; HUMANS; IMMUNITY, INNATE; IMMUNOENZYME TECHNIQUES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77949703823     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.009647     Document Type: Article

References (36)

1. Ramsay AD, Smith WJ, Isaacson PG. T-cellrich B-cell lymphoma. Am J Surg Pathol. 1988;12(6):433-43.
2. Chittal SM, Brousset P, Voigt JJ, Delsol G. Large B-cell lymphoma rich in T-cells and simulating Hodgkin's disease. Histopathology. 1991;19(3):211-20.
3. Delabie J, Vandenberghe E, Kennes C, Verhoef G, Foschini MP, Stul M, et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol. 1992;16(1):37-48.
4. Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. Oncologist. 2006;11(4):384-92.
5. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
6. Lim MS, Beaty M, Sorbara L, Cheng RZ, Pittaluga S, Raffeld M, et al. T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells. Am J Surg Pathol. 2002; 26(11):1458-66.
7. Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. T-cell/histiocyte- rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol. 2002;20(5):1269-77.
8. Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large Bcell lymphoma subtype showing characteristic morphologic and immunophenotypic features. Histopathology. 2002;40(1):31-45.
9. Rudiger T, Gascoyne RD, Jaffe ES, de JD, Delabie J, De Wolf-Peeters C, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyterich B cell lymphoma. Ann Oncol. 2002;13 (Suppl 1):44-51.
10. Brauninger A, Kuppers R, Spieker T, Siebert R, Strickler JG, Schlegelberger B, et al. Molecular analysis of single B cells from Tcell-rich B-cell lymphoma shows the derivation of the tumor cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells. Blood. 1999;93(8):2679-87.
11. Braeuninger A, Kuppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci USA. 1997;94(17):9337-42.
12. Franke S, Wlodarska I, Maes B, Vandenberghe P, Achten R, Hagemeijer A, et al. Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma. Am J Pathol. 2002;161(5):1861-7.
13. Brune V, Tiacci E, Pfeil I, Doring C, Eckerle S, van Noesel CJ, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008;205(10):2251-68.
14. Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999;17(3):776-83.
15. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 351(21):2159-69.
16. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105(5):1851-61.
17. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyons, France: IARC Press; 2008.
18. Boudova L, Torlakovic E, Delabie J, Reimer P, Pfistner B, Wiedenmann S, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocytepredominant Hodgkin lymphoma and Tcell/ histiocyte-rich B-cell lymphoma. Blood. 2003;102(10):3753-8.
19. Franke S, Wlodarska I, Maes B, Vandenberghe P, Delabie J, Hagemeijer A, et al. Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. Blood. 2001;97(6): 1845-53.
20. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
21. Dudoit S, Shaffer JP, Boldrick JC. Multiple hypothesis testing in microarray experiments. Statistical Science. 2003;18:71-103.
22. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25(12):677-86.
23. Billiau A, Matthys P. Interferon-γ: a historical perspective. Cytokine Growth Factor Rev. 2009;20(2):97-113.
24. Van Damme J, Proost P, Put W, Arens S, Lenaerts JP, Conings R, et al. Induction of monocyte chemotactic proteins MCP-1 and MCP-2 in human fibroblasts and leukocytes by cytokines and cytokine inducers. Chemical synthesis of MCP-2 and development of a specific RIA. J Immunol. 1994;152(11):5495-502.
25. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5(11):2516-22.
26. Chon SY, Hassanain HH, Gupta SL. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-γ- inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem. 1996;271(29):17247-52.
27. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147-54.
28. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10): 762-74.
29. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ regulatory T cells. Blood. 2007; 109(7):2871-7.
30. Vogt L, Schmitz N, Kurrer MO, Bauer M, Hinton HI, Behnke S, et al. VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest. 2006; 116(10):2817-26.
31. Helmy KY, Katschke KJ, Jr., Gorgani NN, Kljavin NM, Elliott JM, Diehl L, et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell. 2006;124(5):915-27.
32. Alvaro T, Lejeune M, Camacho FI, Salvado MT, Sanchez L, Garcia JF, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica. 2006;91(12):1605-12.
33. Fraga M, Sanchez-Verde L, Forteza J, Garcia-Rivero A, Piris MA. T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma. Histopathology. 2002;41(3):216-29.
34. Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27(10):1346-56.
35. Nam-Cha SH, Roncador G, Sanchez-Verde L, Montes-Moreno S, Acevedo A, Dominguez-Franjo P, et al. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am J Surg Pathol. 2008;32(8):1252-7.
36. Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer. 2006;6(8):613-25.